DCTH - NASDAQ

Delcath Systems, Inc.

DCTH·NASDAQ

$10.33

-1.9%

HealthcareMedical - Devices

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$356.61M

EPS0.0754

P/E Ratio137.00

Earnings Date08/05/2026

123.63M

Assets

61%

3Y+592.0%

5Y+257.0%

10Y+251.0%

12.41M

Total Liabilities

58%

3Y-48.0%

5Y-1.0%

10Y-66.0%

111.22M

Total Equity

62%

3Y-1998.0%

5Y+404.0%

10Y-7564.0%

Delcath Systems, Inc. Funding & Solvency Profile

DCTH · NASDAQ

Current Assets

Cash & Cash Equivalents43.45M

Net Receivables11.74M

Inventory10.25M

Other Current Assets6.50M

Total Current Assets120 M

Non-Current Assets

Property, Plant & Equipment4.10M

Goodwill & Intangible Assets0.00

Long-Term Investments0.00

Other Non-Current Assets0.00

Total Non-Current Assets4 M

Total Assets

123.63M

Financial Health Analysis

Current Ratio

10.92x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.11x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

109 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

97% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Delcath Systems, Inc. Balance Sheet

DCTH • NASDAQ

Delcath Systems, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012	Dec 2011	Dec 2010	Dec 2009	Dec 2008	Dec 2007	Dec 2006
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	43.5M	32.4M	12.6M	7.7M	22.8M	28.6M	10M	2.5M	4M	4.4M	12.6M	20.5M	31.2M	23.7M	25.8M	45.6M	35.5M	10.8M	7.9M	6.3M
Short-Term Investments	47.6M	20.8M	19.8M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5M	1.5M	0.0	222.7K	0.0	2.4M
Cash & Short-Term Investments	91M	53.2M	32.5M	7.7M	22.8M	28.6M	10M	2.5M	4M	4.4M	12.6M	20.5M	31.2M	23.7M	30.8M	47.1M	35.5M	11M	7.9M	8.7M
Net Receivables	11.7M	11.1M	483K	366K	44K	57K	21K	1.2M	317K	403K	277K	174K	349K	144K	0.0	0.0	0.0	0.0	0.0	0.0
Accounts Receivables	11.7M	10.9M	241K	366K	44K	57K	21K	585K	317K	403K	277K	174K	349K	144K	0.0	0.0	0.0	0.0	0.0	0.0
Other Receivables	0.0	170K	242K	0.0	0.0	0.0	0.0	579K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Inventory	10.3M	6.9M	3.3M	2M	1.4M	855K	654K	858K	1.2M	660K	757K	349K	719K	1.1M	0.0	0.0	0.0	0.0	0.0	0.0
Prepaids	0.0	1.1M	512K	1.9M	2.5M	2.3M	1.8M	191K	551K	648K	625K	591K	784K	844K	1.2M	1.8M	799.4K	353.3K	325.5K	61.9K
Other Current Assets	6.5M	1.4M	387K	4.2M	4.4M	509K	181K	1.2M	1.5M	28M	960K	974K	927K	1.5M	0.0	0.0	0.0	0.0	0.0	0.0
Total Current Assets	119.5M	73.8M	37.2M	16.2M	31.2M	32.3M	12.6M	5.9M	7.6M	34.2M	14.6M	22M	34M	26.4M	32M	48.9M	36.3M	11.3M	18.1M	8.8M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	4.1M	2.8M	1.5M	1.7M	2M	2.3M	1.6M	925K	1.3M	1.1M	1.1M	1.8M	3.1M	4M	3.3M	1.7M	521.3K	17.5K	15K	3.7K
Other Non-Current Assets	0.0	0.0	0.0	0.0	0.0	0.0	-1.6M	0.0	0.0	0.0	0.0	0.0	0.0	-4M	0.0	0.0	0.0	0.0	0.0	0.0
Total Non-Current Assets	4.1M	2.8M	1.5M	1.7M	2M	2.3M	1.6M	925K	1.3M	1.1M	1.1M	1.8M	3.1M	4M	3.3M	1.7M	521.3K	17.5K	15K	3.7K
Total Assets	123.6M	76.6M	38.6M	17.9M	33.1M	34.6M	14.2M	6.8M	8.9M	35.2M	15.7M	23.8M	37.1M	30.5M	35.2M	50.6M	36.8M	11.4M	18.1M	8.8M
LIABILITIES
CURRENT LIABILITIES
Total Payables	2.7M	961K	1M	2M	638K	1.8M	4.5M	7.7M	3.8M	594K	284K	748K	582K	939K	925K	610.5K	754K	703.5K	125.3K	670.4K
Accounts Payable	2.7M	961K	1M	2M	638K	1.8M	4.5M	7.7M	3.8M	594K	284K	748K	582K	939K	925K	610.5K	754K	0.0	125.3K	670.4K
Accrued Expenses	0.0	1.4M	3.3M	3.6M	1.7M	945K	925K	1.8M	1.1M	933K	692K	3.4M	3.3M	1.9M	3.8M	2.6M	1.1M	0.0	0.0	0.0
Short Term Debt	0.0	0.0	10.2M	7.8M	621K	2M	664K	2M	0.0	13.3M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Capital Lease Obligations (Current)	101K	105K	37K	186K	416K	495K	664K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue	0.0	0.0	0.0	0.0	170K	525K	6.9M	3.4M	0.0	30K	0.0	0.0	6K	309K	300K	300M	0.0	0.0	0.0	0.0
Other Current Liabilities	8.2M	3.7M	1.9M	1M	2.4M	4.3M	8.2M	6.2M	2.8M	21.2M	5.3M	464K	2.3M	7.3M	4.1M	18M	11.2M	448.3K	1.6M	0.0
Total Current Liabilities	11M	6.1M	16.4M	14.7M	6M	10M	15.5M	17.8M	7.8M	36.1M	6.3M	4.6M	6.6M	10.2M	8.8M	21.2M	13M	1.2M	1.7M	670.4K
NON-CURRENT LIABILITIES
Long Term Debt	0.0	0.0	0.0	7.8M	15M	0.0	2M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue (Non-Current)	0.0	0.0	0.0	0.0	0.0	2.1M	2.9M	3.4M	0.0	30K	0.0	0.0	6K	309K	300K	300K	0.0	0.0	0.0	0.0
Deferred Tax Liabilities (Non-Current)	0.0	0.0	0.0	0.0	0.0	0.0	-2.9M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Liabilities	628K	766K	6.4M	1.1M	0.0	0.0	0.0	628K	395K	604K	820K	1M	360K	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Non-Current Liabilities	1.5M	1.7M	6.4M	9M	15.2M	2.5M	5.1M	4M	395K	634K	820K	1M	366K	309K	300K	300K	0.0	0.0	0.0	0.0
Capital Lease Obligations	936K	1M	37K	186K	623K	945K	861K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Liabilities	12.4M	7.8M	22.8M	23.7M	21.2M	12.6M	20.6M	21.8M	8.2M	36.7M	7.1M	5.6M	7M	10.5M	9.1M	21.5M	13M	1.2M	1.7M	670.4K
SHAREHOLDERS' EQUITY
Treasury Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-51K	-51K	-51K	-51K	-51K	-51K	-51K	-51.1K	-51.1K	-51.1K	0.0	0.0
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Common Stock	347K	331K	228K	100K	79K	60K	1K	103K	2K	41K	223K	97K	1.3M	768K	482K	430.3K	362.2K	253.6K	252.6K	206.6K
Additional Paid-In Capital	639.1M	599.9M	520.6M	451.6M	432.8M	417.4M	364.8M	329M	325.5M	277.7M	269.7M	264.6M	257.8M	218.1M	172.6M	144.8M	92.8M	57.3M	56.6M	44.7M
Retained Earnings	-528.8M	-531.5M	-505.2M	-457.5M	-421M	-395.3M	-371.2M	-344.1M	-324.8M	-279.2M	-261.2M	-246.5M	-229.1M	-198.8M	-146.9M	-116.1M	-69.4M	-47.3M	-40.5M	-36.8M
Accumulated Other Comprehensive Income/Loss	575K	82K	135K	-83K	18K	-104K	28K	50K	42K	-41K	-8K	20K	96K	37K	0.0	-26.2K	-16.2K	-24.2K	-4.3K	-6.1K
Total Stockholders' Equity	111.2M	68.7M	15.8M	-5.9M	12M	22.1M	-6.4M	-14.9M	678K	-1.5M	8.6M	18.1M	30.1M	20M	26.1M	29.1M	23.8M	10.2M	16.4M	8.1M
Total Equity	111.2M	68.7M	15.8M	-5.9M	12M	22.1M	-6.4M	-14.9M	678K	-1.5M	8.6M	18.1M	30.1M	20M	26.1M	29.1M	23.8M	10.2M	16.4M	8.1M
SUMMARY
Total Liabilities & Equity	123.6M	76.6M	38.6M	17.9M	33.1M	34.6M	14.2M	6.8M	8.9M	35.2M	15.7M	23.8M	37.1M	30.5M	35.2M	50.6M	36.8M	11.4M	18.1M	8.8M
Total Investments	47.6M	20.8M	19.8M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5M	1.5M	0.0	222.7K	0.0	2.4M
Total Debt	936K	1M	10.2M	15.9M	16.3M	2.9M	2.9M	2M	0.0	13.3M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net Debt	-42.5M	-31.4M	-2.5M	8.2M	-6.5M	-25.6M	-7.1M	-478K	-4M	8.9M	-12.6M	-20.5M	-31.2M	-23.7M	-25.8M	-45.6M	-35.5M	-10.8M	-7.9M	-6.3M
Shares Outstanding	34,981,253	34,981,253	34,981,253	34,981,253	34,981,253	34,981,253	34,981,253	34,981,253	34,981,253	34,981,253	34,981,253	34,981,253	34,981,253	34,981,253	34,981,253	34,981,253	34,981,253	34,981,253	34,981,253	34,981,253

SEC Filings

DCTH - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 14, 2026	May 13, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 07, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 07, 2026	May 07, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 02, 2026	May 13, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 03, 2026	March 03, 2026	2026	View Filing
10-K 10-K 2025 FY FY	February 26, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	February 26, 2026	February 26, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 12, 2026	January 09, 2026	2026	View Filing
8-K 8-K 2025 N/A	November 20, 2025	November 19, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 04, 2025	November 04, 2025	2025	View Filing

Showing 1 to 10 of 594 filings

Related Guides

Blog Categories

Continue your DCTH research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.